Journal
CANCERS
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cancers10120506
Keywords
BRCA; DNA-damaging agents; platinum; poly(ADP)-ribose polymerase
Categories
Funding
- SIRIC grant INCa-Inserm-DGOS 1068
- La Ligure contre le Cancer (label EL2016.LNCC/DaB)
- Fondation Ruban Rose
- Institut Paoli-Calmettes
Ask authors/readers for more resources
Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3-5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review, we will summarize clinical trials of chemotherapy and PARP inhibitors (PARPi), alone or in combination, at the early or late stage of BRCA1/2-associated BC. We will also present the mechanisms of resistance to PARPi as well as the new therapeutic strategies of association with PARPi. Finally, we will discuss under which conditions the use of DNA damaging agents can be extended to the BRCA1/2-wild type population, the BRCAness concept.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available